Option Agreement Sample Contracts

Heatwurx, Inc. – License Option Agreement With Concert (April 17th, 2018)
Heatwurx, Inc. – License Option Agreement With Concert (April 16th, 2018)
Network Cn Inc – Amendment No. 12 to Note Exchange and Option Agreement (April 16th, 2018)

This AMENDMENT NO. 12 to the NOTE EXCHANGE AND OPTION AGREEMENT is entered into as of December 28, 2017 (this "Amendment"), by and among KEYWIN HOLDINGS LIMITED, a British Virgin Islands company ("Keywin"), and NETWORK CN INC., a Delaware corporation (the "Company"). Each of the parties hereto is referred to as a "Party" and collectively as the "Parties." Capitalized terms used, but not otherwise defined, herein have the meanings ascribed to such terms in the Original Agreement (as defined below).

Hilton Worldwide Holdings Inc. – Master Amendment and Option Agreement (April 9th, 2018)

THIS MASTER AMENDMENT AND OPTION AGREEMENT (this Agreement), dated as of April 9, 2018, is between Hilton Worldwide Holdings Inc., a Delaware corporation (the Company), HNA Tourism Group Co., Ltd., a Peoples Republic of China (PRC) company (HNA), and HNA HLT Holdco I LLC, a Delaware limited liability company (the Selling Stockholder).

Construction Partners, Inc. – Option Agreement (April 6th, 2018)

THIS OPTION AGREEMENT (this Option Agreement) is made and entered into as of the 7th day of March, 2017 (the Date of Grant) by and between Fred J. Smith, III (Holder) and SunTx CPI Growth Company, Inc., a Delaware corporation (Issuer).

Option Agreement (April 5th, 2018)

Pursuant to the Stock Incentive Plan (the "Plan") of NIKE, Inc., an Oregon corporation (the "Company"), the Company grants to the individual listed below (the "Participant") the right and the option (the "Option") to purchase all or any part of the total shares of the Company's Class B Common Stock ("Shares") granted per the terms and conditions of this agreement between the Company and the Participant (this "Agreement"). By accepting this Option grant, the Participant agrees to all of the terms and conditions of the Plan, the Agreement and any Appendices included with the Agreement. Capitalized terms not explicitly defined in this Agreement but defined in the Plan shall have the same definitions as in the Plan.

Unity Biotechnology, Inc. – Compound Library and Option Agreement (April 5th, 2018)

This Compound Library and Option Agreement (the Agreement), dated as of February 2nd, 2016 (the Signing Date), is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (Ascentage), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (Unity), with a business address at 1700 Owens Street, Suite 535, San Francisco, California 95158. Ascentage and Unity are sometimes referred to herein as individually as a party and collectively as the parties.

Unity Biotechnology, Inc. – First Amendment to Compound Library and Option Agreement (April 5th, 2018)

This Amendment (the Amendment), dated as of March 28, 2018 (the Amendment Effective Date) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (Ascentage), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (Unity), with a business address at 3280 Bayshore Blvd, Suite 100, Brisbane, California 95002. Ascentage and Unity are sometimes referred to herein as individually as a Party and collectively as the Parties.

Novocure Ltd – Form of Performance Option Agreement for Israel Novocure Limited (April 4th, 2018)

AGREEMENT (this "Agreement"), dated as of [____________] between NovoCure Limited, a Jersey Isle company (the "Company" and, collectively with its controlled Affiliates, the "Employer"), and [________________] (the "Participant").

Evaluation and Option Agreement for a Patent License (April 2nd, 2018)

This Evaluation and Option Agreement for a Patent License ("Agreement"), dated as of February 1, 2018 ("Effective Date"), is by and between Actigen Limited ("Patent Holder") Pharmstandard International, S.A. ("Prospective Licensor") and Argos Therapeutics, Inc. ("Prospective Sublicensee").

Unity Biotechnology, Inc. – Compound Library and Option Agreement (March 23rd, 2018)

This Compound Library and Option Agreement (the Agreement), dated as of February 2nd, 2016 (the Signing Date), is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (Ascentage), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (Unity), with a business address at 1700 Owens Street, Suite 535, San Francisco, California 95158. Ascentage and Unity are sometimes referred to herein as individually as a party and collectively as the parties.

Surface Oncology, Inc. – Development and Option Agreement (March 23rd, 2018)

THIS DEVELOPMENT AND OPTION AGREEMENT (the Agreement) is made effective as of July 3, 2014 (the Effective Date), by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and Surface Oncology, Inc., a Delaware corporation having an address at 25 First Street, Suite 303, Cambridge, MA 02141 (Surface).

Hilton Grand Vacations Inc. – Master Amendment and Option Agreement (March 13th, 2018)

THIS MASTER AMENDMENT AND OPTION AGREEMENT (this Agreement), dated as of March 13, 2018, is between Hilton Grand Vacations Inc., a Delaware corporation (the Company), HNA Tourism Group Co., Ltd., a Peoples Republic of China (PRC) company (HNA), and HNA HLT Holdco I LLC, a Delaware limited liability company (the Selling Stockholder).

2018 OPTION AGREEMENT (Non-Qualified Stock Option) (CA Employee) (March 9th, 2018)

This Option Agreement is made as of the __ day of March 2018 between Myers Industries, Inc., an Ohio corporation (hereinafter called the "Company"), and <<full_name>> an employee of the Company or one or more of its Subsidiaries (hereinafter called the "Employee").

2018 OPTION AGREEMENT (Non-Qualified Stock Option) (March 9th, 2018)

This Option Agreement is made as of the __ day of March 2018 between Myers Industries, Inc., an Ohio corporation (hereinafter called the "Company"), and <<full_name>> an employee of the Company or one or more of its Subsidiaries (hereinafter called the "Employee").

Hilton Worldwide, Inc. – Master Amendment and Option Agreement (March 5th, 2018)

THIS MASTER AMENDMENT AND OPTION AGREEMENT (this Agreement), dated as of March 5, 2018, is between Park Hotels & Resorts Inc., a Delaware corporation (the Company), HNA Tourism Group Co., Ltd., a Peoples Republic of China (PRC) company (HNA), and HNA HLT Holdco I LLC, a Delaware limited liability company (the Selling Stockholder).

Amendment of Option Agreement (March 1st, 2018)

This Amendment to Option Agreement ("Amendment") is entered into as of January 15, 2017 by and between Mission Broadcasting, Inc. ("Mission") and Nexstar Broadcasting, Inc. ("Nexstar"). Each of Mission and Nexstar may be referred to herein as a "party" and collectively as the "parties."

Sunlands Online Education Group – Option Agreement (February 23rd, 2018)

This Option Agreement (hereinafter referred to as Agreement) was made as of the 15th day of August, 2017 in Beijing, the Peoples Republic of China (PRC) by and among the parties (hereinafter referred to as Parties) as follows:

TRIPADVISOR, INC. OPTION AGREEMENT (Time-Based) (February 21st, 2018)

THIS OPTION AGREEMENT (this "Agreement"), November 28, 2017 (the "Grant Date"), between TripAdvisor, Inc., a Delaware corporation (the "Company"), and Stephen Kaufer (the "Eligible Individual"), describes the terms of an award ("Award") of an Option to the Eligible Individual by the Company.

Access National Corporation – Access National Corporation Option Agreement - Form Of (January 5th, 2018)

This Stock Option Agreement ("Agreement") evidences the grant to the Optionee set forth below of an option to purchase shares (the "Option") of the common stock (the "Stock") of Access National Corporation (the "Company"), granted under, and subject to the terms and conditions set forth in, the Access National Corporation 2017 Equity Compensation Plan, as the same may be amended or replaced from time to time (the "Plan"), and in addition shall be subject to the terms and conditions set forth below. The Option is intended to be a non-qualified stock option under the Internal Revenue Code. The Option is granted as follows:

Access National Corporation – Access National Corporation Option Agreement - Form Of (January 5th, 2018)

This Stock Option Agreement ("Agreement") evidences the grant to the Optionee set forth below of an option to purchase shares (the "Option") of the common stock (the "Stock") of Access National Corporation (the "Company"), granted under, and subject to the terms and conditions set forth in, the Access National Corporation 2017 Equity Compensation Plan, as the same may be amended or replaced from time to time (the "Plan"), and in addition shall be subject to the terms and conditions set forth below. The Option is intended to be an incentive stock option under the Internal Revenue Code. The Option is granted as follows:

Long Island Iced Tea Corp. – Loan and Option Agreement (December 22nd, 2017)

Court Cavendish Ltd, a company incorporated in England and Wales under no. 04290684, having its registered address at The Care House, Randalls Way, Leatherhead, Surrey, KT22 7TW (the "Lender").

Golden Bull Ltd – Form of Equity Option Agreement (December 22nd, 2017)

This Equity Option Agreement (this "Agreement") is executed by and among the following Parties as of _____, 2017 in Shanghai, the People's Republic of China ("China" or the "PRC"):

Golden Bull Ltd – Form of Equity Option Agreement (December 22nd, 2017)

This Equity Option Agreement (this "Agreement") is executed by and among the following Parties as of ____, 2017 in Shanghai, the People's Republic of China ("China" or the "PRC"):

Monopar Therapeutics – CANCER RESEARCH UK and CANCER RESEARCH TECHNOLOGY LIMITED and MONOPAR THERAPEUTICS LLC CLINICAL TRIAL AND OPTION AGREEMENT (December 20th, 2017)

CANCER RESEARCH UK a company limited by guarantee registered under number 4325234 and a charity registered under number 1089464 of Angel Building, 407 St. John Street, London, EC1V 4AD, England (the "Charity");

Madison Square Garden Co – Option Agreement (December 18th, 2017)

Pursuant to the 2015 Employee Stock Plan (the Plan) of The Madison Square Garden Company (the Company), on December 15, 2017 (the Effective Date) you have been awarded nonqualified options (the Options) to purchase 93,826 shares of the Companys Class A Common Stock, par value $.01 per share (Class A Common Stock) at a price of $210.13 per share. The Award is granted subject to the terms and conditions set forth below and in the Plan.

Carbylan Therapeutics – Option Agreement (December 14th, 2017)

This Asset Purchase and License Agreement (this "Agreement") is entered into as of [*] (the "Agreement Date"), by and between [Merck], a [*] ("Merck"), and KalVista Pharmaceuticals Limited, a private company limited by shares incorporated and registered in England and Wales ("KalVista"). Merck and KalVista may each be referred to herein as a "Party" and collectively as the "Parties".

Option Agreement (December 12th, 2017)

This Membership Interests Purchase Agreement (this Agreement) is entered into as of [___________], 201[__] (the Execution Date), by and among Cardinal Midstream II, LLC, a Delaware limited liability company (Seller), Cardinal NE Holdings, LLC, a Delaware limited liability company (Company), Eclipse Resources Midstream, LP, a Delaware limited partnership and wholly owned subsidiary of Eclipse Parent (Buyer), and, solely for the purposes of Section 9.17 (Parent Guaranty), Eclipse Resources Corporation, a Delaware corporation (Eclipse Parent). In this Agreement, Buyer, Eclipse Parent, Seller and Company are each referred to as a Party and collectively as the Parties.

Converge Global Inc/Ca – Interest Option Agreement (November 27th, 2017)

This Option Agreement to purchase an interest in Conveniant Hemp Mart, LLC ("Option Agreement") certifies that, for value received, Marijuana Company of America, Inc., or its assigns ("Grantee") is entitled to exercise an option to purchase from Conveniant Hemp Mart, LLC., a Wyoming Limited Liability Company ("Company"), an interest equal to twenty-five percent (25%) of the total interests available for sale on the terms and subject to the conditions set forth below and in the Company's Operating Agreement and other offering documents.

Surface Oncology, Inc. – Development and Option Agreement (November 17th, 2017)

THIS DEVELOPMENT AND OPTION AGREEMENT (the Agreement) is made effective as of July 3, 2014 (the Effective Date), by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and Surface Oncology, Inc., a Delaware corporation having an address at 25 First Street, Suite 303, Cambridge, MA 02141 (Surface).

Option Agreement (November 9th, 2017)

Pursuant to your Stock Option Grant Notice ("Grant Notice") and this Option Agreement, Portola Pharmaceuticals, Inc. (the "Company") has granted you an option under its Inducement Plan (the "Plan") to purchase the number of shares of the Company's Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the "Date of Grant"). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.

Monopar Therapeutics – CANCER RESEARCH UK and CANCER RESEARCH TECHNOLOGY LIMITED and MONOPAR THERAPEUTICS LLC CLINICAL TRIAL AND OPTION AGREEMENT (November 9th, 2017)

CANCER RESEARCH UK a company limited by guarantee registered under number 4325234 and a charity registered under number 1089464 of Angel Building, 407 St. John Street, London, EC1V 4AD, England (the "Charity");

American Eagle Group – Ock Option Agreement Pacific Ventures Group, Inc. (November 8th, 2017)

NOW THEREFORE, the Company agrees to offer to the Optionee the option to purchase, upon the terms and conditions set forth herein and in the 2017 Plan, [__________] ([____]) shares of Common Stock. Capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the 2017 Plan.

Snap Inc – Option Agreement Amendment (November 8th, 2017)

This Option Agreement Amendment ("Amendment"), entered into between Tim Sehn (the "Optionee") and Snap Inc., a Delaware corporation (the "Company"), is effective as of November 7, 2017 ("Amendment Effective Date"), and amends that certain Stock Option Grant Notice and Agreement, dated September 6, 2013 (the "Agreement") under the Company's 2012 Equity Incentive Plan (the "Plan"). Capitalized terms used in this Amendment and not defined have the meanings provided to such terms in the Agreement or the Plan, as applicable.

Theravance Biopharma, Inc. – [Form of Notice of Option Grant and Option Agreement Under the Companys Performance Incentive Plan] THERAVANCE BIOPHARMA, INC. PERFORMANCE INCENTIVE PLAN NOTICE OF OPTION GRANT (November 8th, 2017)

This option shall vest and become exercisable with respect to the first 25% of the Ordinary Shares subject to this option on <<FirstVestDate>>, subject to your continuous service as an Employee or Consultant (Service) through such date. This option shall vest and become exercisable with respect to an additional 1/48th of the Ordinary Shares subject to this option when you complete each month of continuous Service thereafter. The option shall be fully vested and exercisable on <<LastVestDate>> provided you have remained in continuous Service through such date.